Oxycodone naltrexone combination clinical trials
Also written ALO-02.
How each study uses oxycodone naltrexone combination is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ALO-02
- 3
Studies by the year they started
4 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses oxycodone naltrexone combination is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered NaltrexoneCompletedPhase 1PfizerNCT01456507Written as ALO-02 (Oxycodone Naltrexone)
- Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With PainTerminatedPhase 4PfizerNCT02680847Written as ALO-02
- A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back PainCompletedPhase 3PfizerNCT01571362Written as ALO-02
- Pharmacokinetics Study of ALO-02 and OxyContinCompletedPhase 1PfizerNCT01557257Written as ALO-02